Dr Matthew McMillan speaks to ecancer about the randomised phase II CURB trial.

This trial investigates tumour burden metrics at oligoprogression and survival after SBRT in NSCLC.

Key findings from this trial show that the sum of longest diameters of growing lesions is a significant metric for patient outcomes.

Patients with lower tumour burdens may benefit from SBRT to progressive sites while continuing current systemic therapy, whereas those with higher burdens might need to consider intensifying or switching systemic therapy.

A median cutoff of four cm was used, identifying patients with this measurement as having significantly longer progression-free survival and overall survival.

Speaking of future strategies, Dr McMillan says it may involve stratifying treatment based on tumour burden, with lower burdens linked to better survival rates.